AstraZeneca supplies to EU, vaccine efficacy for the elderly in focus


A laboratory technicians handles vials of the University of Oxford’s Covid-19 vaccine.


British-Swedish drugmaker AstraZeneca is preventing battles on a number of fronts this week — defending its coronavirus vaccine from stories that it may very well be much less efficient in defending the elderly and going through rising tensions with the EU over its delayed supplies to the bloc.

On Monday, the drugmaker defended its vaccine from stories in a number of German newspapers, Bild and Handelsblatt, that the AstraZeneca vaccine, created in conjunction with the University of Oxford, had a low efficacy fee (of lower than 10% and eight%, the papers mentioned, respectively) in the over-65s, the fundamental goal group for having the vaccine as they’re extra vulnerable to severe illness and dying.

Both cited unnamed officers in Germany’s authorities as saying that the vaccine had a poor efficacy fee amongst individuals aged over 65 and mentioned this might have an effect on whether or not the vaccine is permitted for use amongst the elderly.

AstraZeneca responded Monday night, saying in an announcement to CNBC: “Reports that the AstraZeneca/Oxford vaccine efficacy is as low as 8% in adults over 65 years are completely incorrect.”

“In November, we published data in The Lancet demonstrating that older adults showed strong immune responses to the vaccine, with 100% of older adults generating spike-specific antibodies after the second dose,” it added.

It mentioned the U.Ok.’s Joint Committee on Vaccination and Immunisation, which advises the authorities on its vaccination technique, had supported the vaccine’s use in the elderly.

Elderly trial individuals had been admitted later to section three medical trials of the AstraZeneca vaccine, which came about in the U.Ok. and Brazil, and earlier on in South Africa, and so there may be much less out there information on the efficacy of the shot in the over-65s. Initial trials in the U.Ok. centered on the under-55s to study whether or not the vaccine was efficient for the majority of healthcare staff.

When AstraZeneca printed its trial findings in the medical journal The Lancet in December, it mentioned, “as older age groups were recruited later than younger age groups, there has been less time for cases to accrue and as a result, efficacy data in these cohorts are currently limited by the small number of cases, but additional data will be available in future analyses.” CNBC has contacted AstraZeneca for remark following the stories.

On Tuesday morning, the German well being ministry mentioned there isn’t a information that might recommend an efficacy of solely 8% amongst older individuals for AstraZeneca’s vaccine, Reuters reported.

Supply points

Tensions have been brewing since final week when the drugmaker introduced that manufacturing points would imply it could ship far fewer doses to the EU than had been promised beforehand. The overwhelming majority of the AstraZeneca vaccine for distribution to the EU is being made in the U.Ok.

The EU was meant to obtain 80 million doses of the AstraZeneca vaccine by March, in accordance to a senior unnamed official who spoke to Reuters final Friday, however the drugmaker had knowledgeable the EU that the provide of doses can be lowered to some 31 million doses, a minimize of round 60%.

“This new schedule is not acceptable to the European Union,” EU’s Health Commissioner Stella Kyriakides mentioned in an announcement Monday, signaling that the EU may tighten the guidelines on the exports of Covid-19 vaccines.

“The European Union will take any action required to protect its citizens and rights,” she famous, having acknowledged earlier that “in the future, all companies producing vaccines against Covid-19 in the EU will have to provide early notification whenever they want to export vaccines to third countries.”

Any limitations on vaccine exports from the EU may have an effect on supplies of the Pfizer/BioNTech shot, which is manufactured in Belgium, to the U.Ok.

Commissioner Kyriakides mentioned on Monday that discussions with AstraZeneca representatives had “resulted in dissatisfaction with the lack of clarity and insufficient explanations.”

She added that “EU Member States are united: vaccine developers have societal and contractual responsibilities they need to uphold.” The EU has requested AstraZeneca to present it with an in depth plan of vaccine deliveries and when distribution will happen, with additional discussions set for Wednesday.

AstraZeneca’s vaccine has not but been authorised for use by the European Medicines Agency however Kyriakdes mentioned that might come by the finish of the week.

The concern over AstraZeneca supplies comes on high of 1 from Pfizer and BioNTech who additionally warned in mid-January of quickly lowered output whereas they upgraded their manufacturing capability.

Shortages of provide are a bitter blow to the EU, whose vaccination drive already began (on Dec.27) later than these in the U.Ok. and U.S.

The EU has bought vaccines as a bloc (though some nations have additionally pursued their very own unilateral offers too) with pictures set to be distributed primarily based on inhabitants measurement, however particular person nations’ vaccination rollouts, together with in Germany, have been very sluggish to this point.

Source hyperlink


It’s nice to meet you.

Sign up to receive awesome content in your inbox, every week.

We don’t spam! Read our privacy policy for more info.